Filament Health ships PEX010 to Australia for University of Melbourne trial
Rhelion Life Sciences says its wholly owned subsidiary Filament Health completed shipment of PEX010 to Australia for a University of Melbourne trial of psilocybin-assisted physiotherapy in functional neurological disorder.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.